Thermo Fisher Scientific Delivers LIMS Solution to Leading Canadian Contract Researcher

BRI Biopharmaceutical Research Inc., which offers services for both bioanalytical LC/MS/MS and in vivo DMPK/ADME lines of business, has standardized on Watson LIMS across its facilities in Canada. The company supports drug discovery and development by offering a comprehensive and integrated range of services that help clients reduce the time it takes to bring new drugs to market. The addition of Thermo Scientific Watson LIMS to BRI’s facilities will not only ensure timely delivery of quality results to clients, but will also improve the internal operational efficiency and profitability of the company.

BRI Biopharmaceutical Research Inc. is a specialized contract research laboratory offering a broad array of LC/MS/MS bioanalytical assays that are delivered by highly experienced scientists with specialization in the assays of biomarkers, nucleotides, peptides and synthetic small molecule drugs in support of GLP PK/TK pre-clinical studies and clinical phase I to IV trials. BRI's pre-clinical development services also include in vitro and in vivo drug metabolism studies, including pharmacokinetics animal models and specialized efficacy animal models in support of late-stage drug candidate optimization and selection.

According to Clara Faan, vice president of operations at BRI Biopharmaceutical, “We have a long-term commitment to information technology solutions that enhance our laboratory operations. Watson LIMS is a critical tool in our laboratory infrastructure that enables us to efficiently manage a wide variety of sponsor protocols and provides for the consistent and reliable delivery of data that is required for GLP and FDA submission requirements.”

Thermo Scientific Watson LIMS is a highly specialized, protocol-driven LIMS for drug metabolism and pharmacokinetic (DMPK) studies, and it is now used by 18 of the top 20 global pharmaceutical companies and leading contract research organizations worldwide. BRI Biopharmaceutical Research relies on the comprehensive purpose-built functionality of Watson LIMS to remain at the forefront of the highly competitive contract research market.

Dave Champagne, vice president and general manager for Thermo Fisher’s Informatics business commented, “We’re thrilled to be able to be a part of the strategic expansion of BRI Biopharmaceutical Research. As the biopharmaceutical research field continues to grow here in western Canada, we look forward to providing BRI with the informatics solutions necessary for their ongoing success.”